Drug Update: New Drug Approvals for IBS, Hypoglycemia, EGPA
1. Ibsrela (tenapanor) The USFDA approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Ibsrela is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients. Warning: In young juvenile rats, tenapanor caused death presumed to be due to dehydration and hence, Ibsrela is contraindicated in patients less than 12 years of age.
Related Bookmarks
- Rare Complication Of Antibiotics: Baboon Syndrome
- Need a Quick Smile Makeover? Visit a Cosmetic Dentist in Bristol
- Stay Lice Free at Sports or Band Camp This Summer
- Top Gynec doctors in vashi sector 17 - Thanawala
- Azzalure for sale online
- Tips to Manage Gingivitis by Dentist Epping NSW
- Organic ashwagandha benefits
- Failed Hernia Mesh? Get your Compensation Today
- 3 Amazing Benefits of Meditation for Your Body, Mind and Soul
- What is Sildenafil 100 I Cenforce 100mg
Recent Profiles
888p
Roger Valley
7655bet
Tin79 Com
Smiles On Queen
23win
Luminous Skin Lab
Drake Atkins
8xbet Trang Chu
Hantique